FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462586873> ?p ?o ?g. }

• W2462586873 abstract "Abstract Background: Relapse or refractory disease is a challenging clinical problem in the majority of chronic lymphocytic leukemia (CLL) patients. Treatment influences the clonal composition by selection and eventually induction of additional genetic abnormalities. Aim: To characterize the clonal evolution in relapsed CLL patients by deep-sequencing analysis of mutations in ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53. Patients and Methods: Sequential samples of 20 relapsed CLL patients at three time-points were evaluated: A: at diagnosis (n=16) or in untreated state (n=4), B: at first relapse (n=20) and C: at second relapse (n=2). Patients were treated with diverse treatment schemes and had temporarily achieved either complete or partial remission during the course of the disease. The median time from diagnosis to first-line treatment was 13 months (1 - 169 months). All geneswere sequenced by a deep sequencing approach (Illumina, San Diego, CA). IGHV mutational status was determined by direct Sanger sequencing at time-point A. Chromosome banding analysis (CBA) and FISH data on del(17p), del(11q), trisomy 12 (+12), and del(13q) were available in 33/42 and 36/42 samples, respectively. Results: Initially, samples at first relapse were sequenced. Mutations in SF3B1 (6/20, 30%), TP53 (5/20, 25%), ATM (5/20, 25%), NOTCH1 (4/20, 20%), and SAMHD1 (3/20, 15%) were detected at high frequencies. No mutations were detected in BIRC3 and POT1. In total, 75% of cases presented with at least one mutation (Figure 1): 8 (40%) cases had one, 6 (30%) cases had two and one patient had three genes concomitantly mutated (mut). Patients were also analyzed for IGHV mutational status at diagnosis and presented with unmutated status at a frequency of 85% (17/20). Subsequently, samples from cases with mutations were analyzed at time-point A. In 12/15 (80%) cases the mutations at relapse were already detectable at time-point A with a similar load indicating presence of the main clone before and after chemotherapy. However, in 7/15 (47%) patients new gene mutations were acquired either additionally to existing mutations (n=4) or in previously wild-type cases (n=3). In 5/7 (71%) cases mutations were located in TP53. TP53 mut were the only mutations that were not detected in samples before treatment (sensitivity of 3%). Thus, TP53 mutations might have been initiated by chemotherapy or exist in a minor subclone subsequently selected by chemotherapy. Furthermore, only 4 cases had low-level mutations (3-6% mutation load) at diagnosis in either SAMHD1 or SF3B1 that eventually increased in their burden during disease course. Of note, in two patients a multibranching clonal evolution could be identified (#2, #9). For patient #2 three time-points were analyzed. At diagnosis 2 ATM mutations were detected with mutation loads of about 20%, each. In the course of the disease these mutations were lost, whereas SF3B1 mut showed a stable mutation load in all three time-points of about 40%. In contrast, mutation load of SAMHD1 increased over time from 4% to 87%. CBA was performed at diagnosis and detected independent clones with del(11q) and del(13q). Accordingly, del(11q) detected by FISH at diagnosis was lost and the percentage of cells with del(13q) increased from diagnosis to time-point C. Therefore, patient #2 shows different genetic subclones in parallel that were eradicated or selected by chemotherapy. In patient #9 two SF3B1 mutations were initially detected with the same mutation load of 10%. After treatment one mutation was lost, whereas the load of the second mutation increased indicating at least two different subclones with only one of them being sensitive to chemotherapy. This might be due to different additional aberrations. Indeed, CBA identified two clones: one with +12 alone and one in combination with del(13q). FISH revealed unchanged percentage of +12 at time-point B, whereas del(13q) positive cells were diminished. Conclusions: In 75% of relapsed CLL cases mutations in SF3B1, TP53, ATM, NOTCH1, and SAMHD1 are present at high frequencies. 80% of these mutations are already detectable before treatment initiation representing the main clone. Remarkably, TP53 mutations were the only mutations that were not detected before but only after chemotherapy. Figure 1. Distribution of gene mutations in 15 CLL cases with mutations at diagnosis or before treatment (D) and at relapse (R). Red = mutated, grey = wild-type, white = not analyzed. Figure 1. Distribution of gene mutations in 15 CLL cases with mutations at diagnosis or before treatment (D) and at relapse (R). Red = mutated, grey = wild-type, white = not analyzed. Disclosures Jeromin: MLL Munich Leukemia Laboratory: Employment. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Schabath:MLL Munich Leukemia Laboratory: Employment. Alpermann:MLL Munich Leukemia Laboratory: Employment. Nadarajah:MLL Munich Leukemia Laboratory: Employment. Meggendorfer:MLL Munich Leukemia Laboratory: Employment. Schnittger:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership." @default.
• W2462586873 created "2016-07-22" @default.
• W2462586873 creator A5021480569 @default.
• W2462586873 creator A5023137678 @default.
• W2462586873 creator A5033589906 @default.
• W2462586873 creator A5041448618 @default.
• W2462586873 creator A5043414993 @default.
• W2462586873 creator A5048388170 @default.
• W2462586873 creator A5059817767 @default.
• W2462586873 creator A5065610259 @default.
• W2462586873 creator A5075981878 @default.
• W2462586873 date "2015-12-03" @default.
• W2462586873 modified "2023-09-27" @default.
• W2462586873 title "Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53" @default.
• W2462586873 doi "https://doi.org/10.1182/blood.v126.23.1721.1721" @default.
• W2462586873 hasPublicationYear "2015" @default.
• W2462586873 type Work @default.
• W2462586873 sameAs 2462586873 @default.
• W2462586873 citedByCount "0" @default.
• W2462586873 crossrefType "journal-article" @default.
• W2462586873 hasAuthorship W2462586873A5021480569 @default.
• W2462586873 hasAuthorship W2462586873A5023137678 @default.
• W2462586873 hasAuthorship W2462586873A5033589906 @default.
• W2462586873 hasAuthorship W2462586873A5041448618 @default.
• W2462586873 hasAuthorship W2462586873A5043414993 @default.
• W2462586873 hasAuthorship W2462586873A5048388170 @default.
• W2462586873 hasAuthorship W2462586873A5059817767 @default.
• W2462586873 hasAuthorship W2462586873A5065610259 @default.
• W2462586873 hasAuthorship W2462586873A5075981878 @default.
• W2462586873 hasConcept C104317684 @default.
• W2462586873 hasConcept C113968399 @default.
• W2462586873 hasConcept C121608353 @default.
• W2462586873 hasConcept C126322002 @default.
• W2462586873 hasConcept C132917006 @default.
• W2462586873 hasConcept C141231307 @default.
• W2462586873 hasConcept C143998085 @default.
• W2462586873 hasConcept C2777609679 @default.
• W2462586873 hasConcept C2777938653 @default.
• W2462586873 hasConcept C2778461978 @default.
• W2462586873 hasConcept C51679486 @default.
• W2462586873 hasConcept C54355233 @default.
• W2462586873 hasConcept C71924100 @default.
• W2462586873 hasConcept C76818968 @default.
• W2462586873 hasConcept C86803240 @default.
• W2462586873 hasConceptScore W2462586873C104317684 @default.
• W2462586873 hasConceptScore W2462586873C113968399 @default.
• W2462586873 hasConceptScore W2462586873C121608353 @default.
• W2462586873 hasConceptScore W2462586873C126322002 @default.
• W2462586873 hasConceptScore W2462586873C132917006 @default.
• W2462586873 hasConceptScore W2462586873C141231307 @default.
• W2462586873 hasConceptScore W2462586873C143998085 @default.
• W2462586873 hasConceptScore W2462586873C2777609679 @default.
• W2462586873 hasConceptScore W2462586873C2777938653 @default.
• W2462586873 hasConceptScore W2462586873C2778461978 @default.
• W2462586873 hasConceptScore W2462586873C51679486 @default.
• W2462586873 hasConceptScore W2462586873C54355233 @default.
• W2462586873 hasConceptScore W2462586873C71924100 @default.
• W2462586873 hasConceptScore W2462586873C76818968 @default.
• W2462586873 hasConceptScore W2462586873C86803240 @default.
• W2462586873 hasLocation W24625868731 @default.
• W2462586873 hasOpenAccess W2462586873 @default.
• W2462586873 hasPrimaryLocation W24625868731 @default.
• W2462586873 hasRelatedWork W2285405143 @default.
• W2462586873 hasRelatedWork W2519672061 @default.
• W2462586873 hasRelatedWork W2525895468 @default.
• W2462586873 hasRelatedWork W2525991848 @default.
• W2462586873 hasRelatedWork W2549502239 @default.
• W2462586873 hasRelatedWork W2550433766 @default.
• W2462586873 hasRelatedWork W2554067071 @default.
• W2462586873 hasRelatedWork W2558458407 @default.
• W2462586873 hasRelatedWork W2560376632 @default.
• W2462586873 hasRelatedWork W2562040833 @default.
• W2462586873 hasRelatedWork W2566841786 @default.
• W2462586873 hasRelatedWork W2576733737 @default.
• W2462586873 hasRelatedWork W2580242547 @default.
• W2462586873 hasRelatedWork W2587810752 @default.
• W2462586873 hasRelatedWork W2589130651 @default.
• W2462586873 hasRelatedWork W2595873998 @default.
• W2462586873 hasRelatedWork W2922086159 @default.
• W2462586873 hasRelatedWork W2979538955 @default.
• W2462586873 hasRelatedWork W2980775249 @default.
• W2462586873 hasRelatedWork W3041113374 @default.
• W2462586873 isParatext "false" @default.
• W2462586873 isRetracted "false" @default.
• W2462586873 magId "2462586873" @default.
• W2462586873 workType "article" @default.